Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma

International Journal of Hyperthermia

Volumn 24, Issue 3, 2008, Pages 275-289

  Müller, Mecker G ^a   Lewis, James M ^a   Dessureault, Sophie ^a   Zager, Jonathan S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Extremity melanoma and sarcoma; Hyperthermic perfusion; Limb infusion; Regional and systemic toxicities

Indexed keywords

ANTINEOPLASTIC AGENT; CREATINE KINASE; DACARBAZINE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; FOTEMUSTINE; GAMMA INTERFERON; HEPARIN; HYPERTENSIVE FACTOR; MELPHALAN; MITOMYCIN; PROTAMINE; TUMOR NECROSIS FACTOR ALPHA;

AMPUTATION; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLISTER; BLOOD CELL COUNT; BLOOD VESSEL INJURY; BONE MARROW DEPRESSION; BONE MARROW DISEASE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARTMENT SYNDROME; DEEP VEIN THROMBOSIS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; ERYTHEMA; FASCIOTOMY; GASTROINTESTINAL DISEASE; HAIR LOSS; HEART FAILURE; HEMATOLOGIC DISEASE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYDRATION; HYPERTHERMIC THERAPY; HYPOTENSION; KIDNEY FAILURE; LIMB DISEASE; LIMB PERFUSION; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG EMBOLISM; LYMPH NODE METASTASIS; LYMPHEDEMA; MACULOPAPULAR RASH; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MELANOMA; MONOTHERAPY; MORBIDITY; MUSCULOSKELETAL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUTROPENIA; PAIN; PATIENT CARE; PATIENT MONITORING; POSTOPERATIVE EDEMA; PRURITUS; RANGE OF MOTION; RESPIRATORY TRACT DISEASE; RHABDOMYOLYSIS; SARCOMA; SENSORY NEUROPATHY; SEPSIS; SHOCK; SIDE EFFECT; SKIN DISEASE; SKIN INJURY; SOFT TISSUE INJURY; STOMATITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTOLIC BLOOD PRESSURE; THROMBECTOMY; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED STATES; UROGENITAL TRACT DISEASE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS AS TOPIC; COMPARTMENT SYNDROMES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTHERMIA, INDUCED; LYMPHATIC METASTASIS; MELANOMA; SARCOMA; SEVERITY OF ILLNESS INDEX;

EID: 42049104793     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.1080/02656730701805520     Document Type: Article

References (78)

1. Creech, O., Krementz, ET, Ryan, RF and Winblad, JN (1958) Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit. Ann Surg, 148, pp. 616-632.
2. Thompson, JF, Waugh, RC and Saw, RPM (1994) Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Ref Cancer Treat, 7, pp. 188-190.
3. Eggermont, AM, van Geel, AN, de Wilt, JH and Hagen, TL ten (2003) The role of isolated limb perfusion for melanoma confined to the extremities. Surg Clin North Am, 83, pp. 371-384.
4. Filippo, F Di, Calabro, A., Giannarelli, D., Carlini, S., Cavaliere, F., Moscarelli, F. and Cavaliere, R. (1989) Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer, 63, pp. 2551-2561.
5. Kroon, BBR, Klaase, JM, Geel, AN Ven and Eggermont, AMM (1992) Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg Cancer Treat, 4, pp. 223-226.
6. Eggermont, AM, Koops, H Schraffordt, Klausner, JM, Kroon, BB, Schlag, PM, Liénard, D., van Geel, AN, Hoekstra, HJ, Meller, I. and Nieweg, OE (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg, 224, pp. 756-764.
7. Benckhuijsen, C., Kroon, BB, van Geel, AN and Weiberdink, J. (1988) Regional perfusion treatment with melphalan for melanoma in a limb: An evaluation of drug kinetics. Eur J Surg Oncol, 14, pp. 157-163.
8. Hayes, AJ, Clark, MA, Harries, M. and Thomas, JM (2004) Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg, 91, pp. 673-682.
9. Vrouenraets, BC, Klaase, JM, Nieweg, OE and Kroon, BB (1998) Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol, 14, pp. 224-231.
10. Vrouenraets, BC, Nieweg, OE and Kroon, BB (1996) Thirty-five years of isolated limb perfusion for melanoma: Indications and results. Br J Surg, 83, pp. 1319-1328.
11. Sorkin, P., Abu-Abid, S., Lev, D., Gutman, M., Aderka, D., Halpern, P., Setton, A., Kudlik, N., Bar-On, J. and Rudich, V. (1995) Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg, 130, pp. 1079-1084.
12. Thompson, JK, Kam, PC, Waugh, RC and Harman, CR (1998) Isolated limb infusion with cytotoxic agents: A simple alternative to isolated limb perfusion. Semin Surg Oncol, 14, pp. 238-247.
13. Thompson, JF and Kam, PC (2004) Isolated limb infusion for melanoma: A simple but effective alternative to isolated limb perfusion. J Surg Oncol, 88, pp. 1-3.
14. Zager, JS, Gershenwald, JE, Aldrink, J., Lin, E., Cheng, T., Cormier, JN, Mansfield, PF, Lee, JE, Tyler, DS and Ross, MI (2006) Isolated limb infusion for locally recurrent and in-transit extremity melanoma: A multi institutional experience. Ann Surg Oncol, 13, p. 75.
15. Lindner, P., Thompson, JF, De Wilt, JH, Colman, M. and Kam, PC (2004) Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol, 30, pp. 433-439.
16. Brady, MS, Brown, K., Patel, A., Fisher, C. and Marx, W. (2006) A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol, 13, pp. 1123-1129.
17. Lindner, P., Doubrovsky, A., Kam, P. and Thompson, J. (2002) Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol, 9, pp. 127-136.
18. Bonenkamp, JJ, Thompson, JF, de Wilt, JH, Doubrovsky, A., Lima, R de Faria and Kam, PC (2004) Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol, 30, pp. 1107-1112.
19. Weiberdink, J., Benckhuysen, C., Braat, R., Van Slooten, EA and Olthuis, GA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol, 18, pp. 905-910.
20. Ovrum, E., Lindberg, H., Holen, EA, Abdelnoor, M. and Bech, J. (1991) Systemic and pulmonary circulatory effects of protamine following cardiopulmonary bypass in man. Scand J Thorac Cardiovasc Surg, 25, pp. 19-24.
21. Hoven-Gondrie, ML, Thijssens, KM, Dungen, JJ Van den, Loonstra, J., van Ginkel, RJ and Hoekstra, HJ (2007) Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann Surg Oncol, 14, pp. 2105-2112.
22. Eroǧlu, A., Ozcan, H., Eryavuz, Y., Kocaǧlu, H., Demirci, S. and Aytac, SK (2001) Deep venous thrombosis of the extremity diagnosed by color Doppler ultrasonography after isolated limb perfusion. Tumori, 87, pp. 187-190.
23. Vrouenraets, BC, Kroon, BB and Klaase, JM (1995) Severe acute regional toxicity after normothermic or 'mild' hyperthermic limb perfusion with melphalan for melanoma. Melanoma Res, 5, pp. 425-431.
24. Guadagni, S., Santinami, M., Patuzzo, R., Pilati, PL, Miotto, D., Deraco, M., Rossi, CR, Fiorentini, G., Filippo, F Di and Valenti, M. (2003) Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: A pilot study. Melanoma Res, 13, pp. 51-58.
25. Aloia, TA, Grubbs, E., Onaitis, M., Mosca, PJ, Cheng, TY, Seigler, H. and Tyler, DS (2005) Predictors of outcome after hyperthermic isolated limb perfusion: Role of tumor response. Arch Surg, 140, pp. 1115-1120.
26. Eggimann, P., Chiolero, R., Chassot, PG, Lienard, D., Gerain, J. and Lejeune, F. (1995) Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest, 107, pp. 1074-1082.
27. Grubbs, EG, Abdel-Wahab, O., Cheng, TY, Abdel-Wahab, Z., Peterson, B., Pruitt, SK, Colvin, OM, Friedman, HS and Tyler, DS (2004) In-transit melanoma: The role of alkylating-agent resistance in regional therapy. J Am Coll Surg, 199, pp. 419-427.
28. Vrouenraets, BC, Eggermont, AM, Hart, AA, Klaase, JM, van Geel, AN, Nieweg, OE and Kroon, BB (2001) Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone. Eur J Surg Oncol, 27, pp. 390-395.
29. Rossi, CR, Mocellin, S., Pilati, P., Foletto, M., Campana, L., Quintieri, L., De Salvo, GL and Lise, M. (2005) Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas. Ann Surg Oncol, 12, pp. 1-8.
30. Grünhagen, DJ, de Wilt, JH, Graveland, WJ, Verhoef, C., van Geel, AN and Eggermont, AM (2005) Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer, 106, pp. 1776-1784.
31. Bonvalot, S., Laplanche, A., Lejeune, F., Stoeckle, E., Pechoux, C Le, Vanel, D., Terrier, P., Lumbroso, J., Ricard, M. and Antoni, G. (2005) Limb salvage with isolated perfusion for soft tissue sarcoma: Could less TNF-alpha be better?. Ann Oncol, 16, pp. 1061-1068.
32. Noorda, EM, Vrouenraets, BC, Nieweg, OE, van Coevorden, F., van Slooten, GW and Kroon, BB (2003) Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer, 98, pp. 1483-1490.
33. Noorda, EB, Vrouenraets, BC, Nieweg, OE, van Geel, B., Eggermont, AM and Kroon, BB (2004) Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg, 139, pp. 1237-1242.
34. Müller, MG, Zager, JS, Lewis, JM, Dessureault, D., Kim, C., Puleo, C., Reintgen, D. and Letson, DG (2007) Single agent experience for hyperthermic isolated limb perfusion of extremity sarcomas. Ann Surg Oncol, 14, p. 72.
35. Cornett, WR, McCall, LM, Petersen, RP, Ross, MI, Briele, HA, Noyes, RD, Sussman, JJ, Kraybill, WG, Kane III, JM and Alexander, HR (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol, 24, pp. 4196-4201.
36. Bulman, AS and Jamieson, CW (1980) Isolated limb perfusion with melphalan in the treatment of malignant melanoma. Br J Surg, 67, pp. 660-662.
37. Klicks, RJ, Vrouenraets, BC, Nieweg, OE and Kroon, BB (1998) Vascular complications of limb perfusion. Eur J Surg Oncol, 24, pp. 288-291.
38. Klicks, RJ (1995) p. 46.
39. Pennacchioli, E., Deraco, M., Mariani, L., Fiore, M., Mussi, C., Collini, P., Olmi, P., Casali, PG, Santinami, M. and Gronchi, A. (2007) Advanced extremity soft tissue sarcoma: Prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol, 14, pp. 553-559.
40. Hayes, AJ, Neuhaus, SJ, Clark, MA and Thomas, JM (2007) Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma. Ann Surg Oncol, 14, pp. 230-238.
41. Grunhagen, DJ, de Wilt, JH, Graveland, WJ, van Geel, AN and Eggermont, AM (2005) The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer, 106, pp. 156-162.
42. Knorr, C., Meyer, T., Janssen, T., Goehl, J. and Hohenberger, W. (2006) Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience with 101 patients. Eur J Surg Oncol, 32, pp. 224-227.
43. Vrouenraets, BC, Klaase, JM, Kroon, BB, van Geel, BN, Eggermont, AM and Franklin, HR (1995) Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg, 130, pp. 43-47.
44. Vrouenraets, BC, Keus, RB, Nieweg, OE and Kroon, BB (1997) Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors. J Surg Oncol, 65, pp. 88-94.
45. Olieman, AF, Koops, H Schraffordt, Geertzen, JH, Kingma, H., Hoekstra, HJ and Oldhoff, J. (1994) Functional morbidity of hyperthermic isolated regional perfusion of the extremities. Ann Surg Oncol, 1, pp. 382-388.
46. Vrouenraets, BC, Veld, GJ in't, Nieweg, OE, van Slooten, GW, van Dongen, JA and Kroon, BB (1999) Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur J Surg Oncol, 25, pp. 503-508.
47. van Geel, AN, van Wijk, J. and Weiberdink, J. (1989) Functional morbidity after regional isolated perfusion of the limb for melanoma. Cancer, 63, pp. 1092-1096.
48. Vrouenraets, BC, Eggermont, AM, Klaase, JM, Van Geel, BN, Van Dongen, JA and Kroon, BB (1994) Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs. Eur J Surg Oncol, 20, pp. 681-685.
49. Noorda, EM, Vrouenraets, BC, Nieweg, OE, van Geel, AN, Eggermont, AM and Kroon, BB (2006) Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol, 32, pp. 318-324.
50. Grünhagen, DJ, van Etten, B., Brunstein, F., Graveland, WJ, van Geel, AN, de Wilt, JH and Eggermont, AM (2005) Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol, 12, pp. 609-615.
51. Klaase, JM, Kroon, BB, van Geel, AN, Eggermont, AM, Franklin, HR and van Dongen, JA (1993) A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb. Cancer, 71, pp. 2990-2994.
52. Kroon, BB, Klaase, JM, van Geel, BN, Eggermont, AM, Franklin, HR and van Dongen, JA (1993) Results of a double perfusion schedule with melphalan in patients with melanoma of the lower limb. Eur J Cancer, 29, pp. 325-328.
53. Krementz, ET, Ryan, RF, Carter, RD, Sutherland, KM and Reed, RJ (1985) Hyperthermic regional perfusion of the limbs. Cutaneous melanoma: Clinical management and treatment worldwide, pp. 171-190. Lippincott, Philadelphia
54. Miller, AB, Hoogstraten, B., Staquet, M. and Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, pp. 207-214.
55. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (2006)
56. Sonneveld, EJ, Vrouenraets, BC, van Geel, Bn, Eggermont, Am, Klaase, JM, Nieweg, OE, van Dogen, JA and Kroon, BB (1996) Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol, 22, pp. 521-527.
57. Zwaveling, JH, Maring, JK, Clarke, FL, van Ginkel, RJ, Limburg, PC, Hoekstra, HJ, Koops, HS and Girbes, AR (1996) High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. Crit Care Med, 24, pp. 765-770.
58. Renard, N., Liénard, D., Lespagnard, L., Eggermont, A., Heimann, R. and Lejeune, F. (1994) Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer, 57, pp. 656-663.
59. Lewis, JM, Sander, G., Reintgen, D. and Letson, DG (2006) Hyperthermic limb perfusion: Evolving concepts in the treatment of extremity soft tissue sarcoma. Curr Opin Orthop, 17, pp. 1-5.
60. Lans, TE, Grünhagen, DJ, de Wilt, JH, van Geel, AN and Eggermont, AM (2005) Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol, 12, pp. 406-411.
61. Furner, RL and Brown, RK (1980) L-phenylalanine mustard (L-PAM): The first 25 years. Cancer Treat Rep, 64, pp. 559-574.
62. Hoekstra, HJ, Naujocks, T. and Koops, H Schraffordt (1992) Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: Techniques and results. Reg Cancer Treat, 4, pp. 301-304.
63. Landefeld, CS and Byeth, RJ (1993) Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med, 95, pp. 315-328.
64. Love, DG (1999) Management of hemorrhagic events in patients receiving anticoagulant therapy. J Thromb Thrombolysis, 7, pp. 149-152.
65. Brener, SJ, Moltinero, DJ, Lincoff, AM, Steinhubl, SR, Wolski, KE and Topol, EJ (2004) Relationship between activated clotting time and ischemic or hemorrhagic complications. Analysis of four recent randomized clinical trials of percutaneous coronary intervention. Circulation, 110, pp. 994-998.
66. Warkentin, TE and Greinacher, A. (2003) Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg, 76, pp. 2121-2131.
67. Warkentin, TE and Hematology (2003) Heparin-induced thrombocytopenia: Pathogenesis and management. Br J Haematol, 123, pp. 373-374.
68. Weiler, JM, Gellhaus, MA and Carter, JG (1990) A prospective study of the risk of an immediate adverse reaction to protamine sulfate during cardiopulmonary bypass surgery. J Allergy Clin Immunol, 85, pp. 713-719.
69. Wakefield, TW, Hantler, CB, Wrobleski, SK, Crider, BA and Stanley, JC (1996) Effects of differing rates of protamine reversal of heparin anticoagulation. Surgery, 119, pp. 123-128.
70. Carr, JA and Silverman, N. (1999) The heparin-protamine interaction. J Cardiovasc Surg (Torino), 40, pp. 659-666.
71. Gupta, SK, Veith, FJ and Ascer, E. (1988) Anaphylactoid reactions to protamine: An often lethal complication in insulin-dependent patients undergoing vascular surgery. J Vasc Surg, 9, pp. 342-350.
72. Vrouenraets, BC, Hart, GA, Eggermont, AM, Klaase, JM, van Geel, BN, Nieweg, OE and Kroon, BB (1999) Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg, 188, pp. 522-530.
73. Cheng, TY, Grubbs, E., Abdul-Wahab, O., Leu, SY, Hung, CF, Petros, W., Aloia, T., Fedrau, R., Pruitt, SK and Colvin, M. (2003) Marked variability of melphalan drug levels during regional hyperthermic isolated limb perfusion. Am J Surg, 186, pp. 460-467.
74. Grünhagen, DJ, Brunstein, F., Graveland, WJ, van Geel, AN, de Wilt, JHW and Eggermont, AM (2004) One hundred consecutive isolated limb perfusions with TNF- and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg, 240, pp. 939-948.
75. Grünhagen, DJ, Brunstein, F., Graveland, WJ, Van Geel, A., De Wilt, JW and Eggermont, AM (2005) Isolated limb perfusion with tumor necrosis factor and melphalan prevents amputation in patients with multiple sarcomas in arm or leg. Ann Surg Oncol, 12, pp. 1-7.
76. Grünhagen, DJ, de Wilt, JH, van Geel, AN, Graveland, WJ, Verhoef, C. and Eggermont, AM (2005) TNF dose reduction in isolated limb perfusion. Eur J Surg Oncol, 31, pp. 1011-1019.
77. Rossi, CR, Lejeune, FJ, Pontes, L., Foletto, M., De Salvo, GL, Pilati, PL, Mocellin, S., Ribeiro, M., Lopes, M. and Lise, M. (2003) Phase I-II study on isolation antiblastic fotemustine perfusion after dacarbazine chemosensitisation for advanced melanoma of the extremities. Melanoma Res, 13, pp. 293-297.
78. Rossi, CR, Foletto, M., Mocelli, S., Pilati, P. and Lise, M. (2004) Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-α and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol, 11, pp. 173-177.